Summary & Overview
HCPCS Level II J2310: Injection, Naloxone Hydrochloride, per 1 mg
HCPCS Level II code J2310 denotes the product dose for naloxone hydrochloride injection, billed per 1 mg. Naloxone is a life-saving opioid antagonist used for rapid reversal of opioid overdose, and accurate coding supports clinical documentation, inventory management, and payer reimbursement across acute care settings. Nationally, consistent use of J2310 facilitates reporting for emergency care, hospital administrations, and outpatient clinics that provide injectable naloxone.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. The publication outlines how J2310 is applied across typical sites of service — emergency departments, urgent care, inpatient units, and ambulatory clinics — and how payers commonly process claims for injectable naloxone.
Readers will find benchmarks for utilization and allowed amounts where available, summaries of payer coverage patterns, relevant policy and coding guidance updates, and clinical context on naloxone administration. The report also highlights common billing considerations and service-line implications for facilities that stock and administer naloxone. Data not available in the input will be noted where necessary.
Billing Code Overview
HCPCS Level II code J2310 represents injection, naloxone hydrochloride, per 1 mg. This code is used to report administration or supply of naloxone hydrochloride in 1 mg increments for reversal of opioid overdose.
Service Type: Medication administration / injectable opioid antagonist
Typical Site of Service: Emergency department, ambulatory clinic, urgent care, inpatient setting, or other acute care locations where injectable naloxone may be administered
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A 32-year-old adult with known opioid use disorder is brought to the emergency department by ambulance after suspected opioid overdose with decreased consciousness and respiratory depression. On arrival, the emergency clinician assesses airway, breathing, and circulation, obtains a brief history from EMS and bystanders, and documents vital signs and pulse oximetry. When pinpoint pupils, hypoventilation, and poor response to verbal stimuli are observed, the clinician administers J2310 (injection, naloxone hydrochloride, per 1 mg) intravenously or intramuscularly per local protocol to reverse opioid effects. The medication may be titrated in 1 mg increments until adequate spontaneous respirations and protective airway reflexes return. After initial stabilization, the patient is monitored for recurrent respiratory depression and withdrawal symptoms; additional doses of naloxone may be given or continuous infusion arranged if long-acting opioids are suspected. Documentation includes indication, dose(s) administered, route, patient response, time stamps, and any complications. Disposition options include observation in the emergency department, admission for airway monitoring, or transfer to detoxification services and linkage to outpatient addiction treatment as clinically appropriate.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
11 | Professional component | Use when reporting the professional component of a bundled service when applicable to billed service lines (rare for single-drug HCPCS). |